Sarepta Therapeutics Names Jean-Paul Kress To Board
This article was originally published in Scrip
Sarepta Therapeutics, a company developing RNA-targeted therapies, has appointed Jean-Paul Kress to its board of directors. Kress is currently head of Sanofi Genzyme speciality care business unit in North America and before this he was president and CEO of Sanofi Pasteur MSD.Previously, Kress was at Gilead as vice-president and general manager in France.
Register for our free email digests: